Related Experiment Video
Updated: Jun 26, 2025
Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study
Lusheng Miao1, Taosheng Miao2, Ying Zhang1
1Department of Dermatology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Background:
Melanoma proliferation is partly attributed to dysregulated lipid metabolism. The effectiveness of lipid-lowering drugs in combating cutaneous melanoma (CM) is a subject of ongoing debate in both in vitro and clinical studies.
Method:
This study aims to evaluate the causal relationship between various lipid-lowering drug targets, namely 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR, targeted by statins), Proprotein convertase subtilisin/kexin type 9 (PCSK9, targeted by alirocumab and evolocumab), and Niemann-Pick C1-like 1 (NPC1L1, targeted by ezetimibe), and the outcomes of cutaneous melanoma. To mimic the effects of lipid-lowering drugs, we utilized two genetic tools: analysis of polymorphisms affecting the expression levels of drug target genes, and genetic variations linked to low-density lipoprotein cholesterol levels and drug target genes. These variations were sourced from genome-wide association studies (GWAS). We applied Summary-data-based Mendelian Randomization (SMR) and Inverse Variance Weighted Mendelian Randomization (IVW-MR) to gauge the effectiveness of these drugs.
Results:
Our findings, with SMR results showing an odds ratio (OR) of 1.44 (95% CI: 1.08-1.92; P = 0.011) and IVW-MR results indicating an OR of 1.56 (95% CI: 1.10-2.23; P = 0.013), demonstrate a positive correlation between PCSK9 expression and increased risk of CM. However, no such correlations were observed in other analyses.
Conclusion:
The study concludes that PCSK9 plays a significant role in the development of CM, and its inhibition is linked to a reduced risk of the disease.
Insights
Elevated PCSK9 expression increases cutaneous melanoma risk. Inhibiting PCSK9 may reduce the risk of developing this skin cancer.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Melanoma proliferation is linked to altered lipid metabolism.
- The role of lipid-lowering drugs in cutaneous melanoma (CM) treatment remains debated.
- Investigating genetic targets of lipid-lowering drugs offers insights into CM development.
Purpose of the Study:
- To investigate the causal relationship between key lipid-lowering drug targets and CM outcomes.
- To evaluate the impact of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), Proprotein convertase subtilisin/kexin type 9 (PCSK9), and Niemann-Pick C1-like 1 (NPC1L1) on CM risk.
- To leverage genetic variations to mimic the effects of lipid-lowering medications.
Main Methods:
- Utilized genome-wide association study (GWAS) data for genetic variations.
- Employed Summary-data-based Mendelian Randomization (SMR) and Inverse Variance Weighted Mendelian Randomization (IVW-MR).
- Analyzed polymorphisms affecting drug target gene expression and LDL cholesterol levels.
Main Results:
- A significant positive correlation was found between PCSK9 expression and increased CM risk (SMR OR: 1.44, IVW-MR OR: 1.56).
- No significant correlations were observed for other lipid-lowering drug targets (HMGCR, NPC1L1) or other analyses.
- These results suggest PCSK9 is a potential factor in CM development.
Conclusions:
- PCSK9 plays a significant role in the pathogenesis of cutaneous melanoma.
- Inhibition of PCSK9 is associated with a reduced risk of developing CM.
- Targeting PCSK9 may represent a novel therapeutic strategy for CM prevention or treatment.
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
